Fusion Pharm Financials
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion |
Understanding current and past Fusion Pharm Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Fusion Pharm's financial statements are interrelated, with each one affecting the others. For example, an increase in Fusion Pharm's assets may result in an increase in income on the income statement.
Fusion Pharm Stock Summary
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people.Specialization | Consumer Staples, Consumer Staples Distribution & Retail |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US36113H1005 |
| Business Address | 5850 East 58th |
| Sector | Consumer Staples Distribution & Retail |
| Industry | Consumer Staples |
| Benchmark | Dow Jones Industrial |
| Website | www.fusionpharminc.com |
| Phone | 720 458 0686 |
| Currency | USD - US Dollar |
Fusion Pharm Key Financial Ratios
| Return On Asset | -1.38 | ||||
| Beta | -20.67 |
Fusion Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharm's current stock value. Our valuation model uses many indicators to compare Fusion Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fusion Pharm competition to find correlations between indicators driving Fusion Pharm's intrinsic value. More Info.Fusion Pharm is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in profit margin category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Fusion Pharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fusion Pharm Systematic Risk
Fusion Pharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Fusion Pharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Fusion Pharm correlated with the market. If Beta is less than 0 Fusion Pharm generally moves in the opposite direction as compared to the market. If Fusion Pharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Fusion Pharm is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Fusion Pharm is generally in the same direction as the market. If Beta > 1 Fusion Pharm moves generally in the same direction as, but more than the movement of the benchmark.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.